Neuromodulation and Language Acquisition (Project Stage Ia)
The purpose of this study is to determine whether levodopa, pergolid, rivastigmine, or modafinil are effective in boosting semantic language acquisition in healthy subjects.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||Improved Language Acquisition Through Neuromodulation, Project Stage Ia|
- Boost in language learning success through neuromodulation
- Stability of language learning success
|Study Start Date:||March 2004|
|Estimated Study Completion Date:||April 2005|
Our prior work shows that d-amphetamine and the dopamine precursor levodopa markedly improve word learning success in healthy subjects. In this randomized, placebo-controlled, double-blind clinical trial, we probe whether a mixed d1/d2 dopamine agonist (pergolid) or cholinergic neuromodulation (rivastigmine) or a general centrally arousing substance (modafinil) will yield a learning enhancement comparable to using levodopa in healthy subjects.
Our results show that the dopamine agonist pergolide impaired learning in healthy subjects compared to placebo, whereas cholinergic neuromodulation had no effect.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00102284
|Dept. of Neurology, University Hospital Muenster|
|Muenster, Nordrhein-Westfalen, Germany, 48129|
|Study Director:||Caterina Breitenstein, PhD||Dept. of Neurology, University Hospital Muenster|
|Study Chair:||Stefan Knecht, MD||Dept. of Neurology, University Hospital Muenster|